Retrophin (RTRX) PT Raised to $32 at Leerink Partners Following Clear Efficacy from Sparsentan

September 7, 2016 12:54 PM EDT
Get Alerts RTRX Hot Sheet
Price: $19.31 -1.18%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade RTRX Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst Joseph Schwatz reiterated an Outperform rating and boosted his price target on Retrophin (NASDAQ: RTRX) to $32.00 (from $27.00) after the company announced positive top-line results for Phase 2b DUET study of sparsentan in focal segmental glomerulosclerosis (FSGS) this morning and they spoke with management following the results conference.

"We are very optimistic that sparsentan will be approved but it remains to be seen whether today's results will support accelerated approval (AA) or if another clinical trial is needed," Schwatz said.

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $16.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment